Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension

KLF2诱导的外泌体microRNA在肺动脉高压中的治疗潜力

阅读:2
作者:Hebah A Sindi # ,Giusy Russomanno # ,Sandro Satta ,Vahitha B Abdul-Salam ,Kyeong Beom Jo ,Basma Qazi-Chaudhry ,Alexander J Ainscough ,Robert Szulcek ,Harm Jan Bogaard ,Claire C Morgan ,Soni S Pullamsetti ,Mai M Alzaydi ,Christopher J Rhodes ,Roberto Piva ,Christina A Eichstaedt ,Ekkehard Grünig ,Martin R Wilkins ,Beata Wojciak-Stothard

Abstract

Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced, while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heritable PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells and attenuates disease progression in PAH mice. This study shows that reduced KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular remodelling.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。